Tandem Diabetes Care (TNDM) Liabilities and Shareholders Equity (2013 - 2026)

Tandem Diabetes Care (TNDM) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $1.2 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 25.08% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 billion (changed 0.0% YoY) and the FY2025 annual result came in at $881.1 million, down 8.94% from the prior year.
• Liabilities and Shareholders Equity rose to $1.2 billion in Q1 2026, from $881.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q1 2026 to a low of $874.7 million in Q3 2025.
• A 5-year average of $968.0 million and a median of $952.7 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 34.6% — and 2023, when it retreated 10.27%.
• Tracing TNDM's Liabilities and Shareholders Equity over 5 years: stood at $1.1 billion in 2022, then dropped by 9.51% to $952.7 million in 2023, then grew by 1.57% to $967.7 million in 2024, then fell by 8.94% to $881.1 million in 2025, then jumped by 30.9% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q1 2026), $881.1 million (Q4 2025), and $874.7 million (Q3 2025), per Business Quant data.